Equity Overview
Price & Market Data
Price: $0.46
Daily Change: +$0.0191 / 4.15%
Daily Range: $0.441 - $0.46
Market Cap: $31,621,285
Daily Volume: 20,364
Performance Metrics
1 Week: 0.11%
1 Month: -27.31%
3 Months: -34.08%
6 Months: -32.25%
1 Year: -30.50%
YTD: -34.27%
Company Details
Employees: 18
Sector: Health technology
Industry: Biotechnology
Country: Canada
Details
Medicenna Therapeutics Corp., a clinical-stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer, inflammation, and immune-mediated diseases. It develops bizaxofusp, an interleukin- 4 (IL-4) targeted therapy for the treatment of recurrent glioblastoma. The company also develops MDNA11, a long-acting interleukin-2 (IL-2) to activate anti-cancer immune cells over immunosuppressive Tregs; MDNA209, an IL-2/IL-15 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host diseases; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; MDNA113, a tumor-targeting and activatable masked anti-PD-1-IL-2 BiSKITTM for cancer; and MDNA132, an IL-13 Superkine for various tumors. Medicenna Therapeutics Corp. is headquartered in Toronto, Canada.